CClinicalTrials.gg
Sign In
CompletedNCT06213506Updated Sep 21, 2026

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants

A Phase 2 interventional study of iNTS-GMMA Dose C and iNTS-GMMA Dose B in Salmonella Infections, sponsored by GlaxoSmithKline. Completed at 1 site in Ghana. Open to participants aged 6 Weeks to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
6 Weeks to 50 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, reactogenicity, and immune response of the GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-generalized modules for membrane antigens (iNTS-GMMA) candidate vaccine against S. Typhimurium and S. Enteritidis with an age de-escalation and dose escalation approach in African population, starting with adults (18-50 years of age), then in children (24-59 months of age) and finally in infants (9 months and 6 weeks of age). Infants are the target for primary vaccination from 6 weeks of age.

Read the detailed description

The study will be conducted as follows:

  • Adult participants will receive either iNTS-GMMA Dose C (high) or a control vaccine intramuscularly on Day 1 and Day 57.
  • Child participants will receive either Dose B (medium) or Dose C (high) of the candidate vaccine or the control on Day 1 and Day 57.
  • Infant participants (9 months of age) will receive either Dose A (low), Dose B (medium), or Dose C (high) of the candidate vaccine or the control on Day 1, Day 85, and Day 169.
  • Infant participants (6 weeks of age) will receive either Dose A (low), Dose B (medium), or Dose C (high) of the candidate vaccine or the control on Day 1, Day 57 and Day 232.
02

Conditions studied

  • Salmonella Infections

Keywords

  • GVGH iNTS-GMMA vaccine
  • Safety
  • Reactogenicity
  • Immunogenicity
  • sub-Saharan Africa
  • African adults
  • children and infants
  • Age de-escalation
  • Invasive nontyphoidal Salmonella
03

In context

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.

Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Weeks to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

All participants (adults, children, infants at 9 months of age and infants at 6 weeks of age) will be enrolled in the clinical site in Ghana and must satisfy ALL the following criteria at study entry:

  • Participants and/or participants' parent(s)/Legally Acceptable Representative(s) (LAR), who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits).
  • Written or witnessed/thumb printed informed consent obtained from the participant/parent(s)/LAR(s) of the participant prior to performance of any study-specific procedure.
  • Healthy participants as established by medical history, clinical examination, and laboratory investigations.
  • Participants satisfying screening requirements.
  • Participants negative for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C.

Adult participants must satisfy ALL the following criteria in the study entry:

  • A male or female between and including 18 and 50 years of age at the time of the first study intervention administration.
  • Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.

  • Female participants of childbearing potential may be enrolled in the study, if the participant:

    • has practiced adequate contraception for 1 month prior to the study intervention administration, and
    • has a negative pregnancy test on the day of study intervention administration, and
    • has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration series.

The Ghana card will be used as source document to verify the ages for the adults.

Child participants must satisfy ALL the following criteria at study entry:

  • A male or female between and including 24 and 59 months of age at the time of the first study intervention administration.
  • Previously completed routine childhood vaccinations to the best knowledge of the participant's parent(s)/LAR's.
  • Born after a gestation period of ≥37 weeks.

Infant participants must satisfy ALL the following criteria at study entry:

  • A male or female 6 weeks or 9 months of age at the time of the first study intervention administration.
  • Born after a gestation period of ≥37 weeks.
  • Born to a mother seronegative for HIV, hepatitis B virus and hepatitis C virus.

The Road to Health Chart will be used as source document to confirm the ages for the children and infants.

Exclusion criteria

Exclusion criteria:

Medical conditions

  • Known exposure to S. Typhimurium or S. Enteritidis during the period starting at birth for infants and children, and at 3 years for adults, as documented by patient records
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions.
  • Hypersensitivity, including allergy, to medicinal products or medical equipment whose use is foreseen in this study.
  • Progressive, unstable, or uncontrolled clinical conditions.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination
  • Major congenital defects, as assessed by the investigator.
  • Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination or laboratory screening tests.
  • Acute disease and/or fever at the time of enrollment (fever is defined as temperature ≥ 38.0°C).
  • Recurrent history or uncontrolled neurological disorders or seizures.
  • Any clinically significant hematological and/or biochemical laboratory abnormality.
  • Undernutrition defined as World Health Organization (WHO) Z-score less than -2 standard deviation (SD).
  • Malaria infection defined as the presence of asexual parasites in the blood.
  • Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
  • Any behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the study.
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.

Prior/Concomitant therapy

  • History of receiving any investigational iNTS or GMMA vaccines in the participant's life.
  • Use of any investigational or non-registered product other than the study interventions during the period beginning 30 days before the first dose of study interventions, or their planned use during the study period.
  • Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 14 days before each dose and ending 28 days after the last dose of study interventions administration, with the exception of flu vaccines and vaccines administered as part of a public health vaccination campaign.

  • A vaccine not foreseen by the study protocol administered during the period starting at 14 days before the first dose and ending 14 days after the last dose of study interventions administration for live vaccines or 7 days in case of inactivated vaccines*, with the exception of flu vaccines or COVID-19 vaccine which may be considered on a case-by-case basis.

    • If emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is organized by public health authorities outside the routine immunization program, the time period described above can be reduced if, provided it is used according to the local governmental recommendations and Sponsor is notified.

Under such circumstances, a participant may be considered eligible for study enrollment and/or study intervention administration after the appropriate window for delay has passed and inclusion/exclusion criteria have been re-checked, and if the participant is confirmed to be eligible.

  • Administration of long-acting immune-modifying drugs at any time during the study period.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives from birth (for infants 6 weeks of age) or during the period starting 3 months before the administration of the first dose of study intervention(s) or planned administration during the study period.
  • Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first study intervention dose(s) up to the end of the study. For corticosteroids, this will mean prednisone equivalent >=20 mg/day for adult participants/ >=0.5 mg/kg/day with maximum of 20 mg/day for pediatric participants (infants and children). Inhaled and topical steroids are allowed.

Prior/Concurrent clinical study experience

  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (vaccine, drug and device).

Other exclusions

  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue contraceptive precautions.
  • History of/current chronic alcohol consumption and/or drug abuse. This will be decided at the discretion of the investigator.
  • Any study personnel or their immediate dependents, family, or household members.
  • Child in care.
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Adults_Dose C Group

    Adults, 18-50 years of age, will receive 2 doses of the iNTS-GMMA Dose C (high dose) vaccine at Day 1 and Day 57.

    Biological: iNTS-GMMA Dose C

  • Active comparator
    Adults_Control Group

    Adults, 18-50 years of age, will receive 1 dose of the MenACWY vaccine at Day 1 and 1 dose of Placebo at Day 57.

    Biological: MenACWY · Drug: Placebo

  • Experimental
    Children_Dose B Group

    Children, 24-59 months of age, will receive 2 doses of the iNTS-GMMA Dose B (medium dose) vaccine at Day 1 and Day 57.

    Biological: iNTS-GMMA Dose B

  • Active comparator
    Children_Control B Group

    Children, 24-59 months of age, will receive 2 doses of the MenACWY vaccine at Day 1 and Day 57.

    Biological: MenACWY

  • Experimental
    Children_Dose C Group

    Children, 24-59 months of age, will receive 2 doses of the iNTS-GMMA Dose C (high dose) vaccine at Day 1 and Day 57.

    Biological: iNTS-GMMA Dose C

  • Active comparator
    Children_Control C Group

    Children, 24-59 months of age, will receive 2 doses of the MenACWY vaccine at Day 1 and Day 57.

    Biological: MenACWY

  • Experimental
    Infants_9M_Dose A Group

    Infants, 9 months of age, will receive 3 doses of the iNTS-GMMA Dose A (low dose) vaccine at Day 1, Day 85 and Day 169. These infants will also receive an Expanded Program on Immunization (EPI) vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.

    Biological: iNTS-GMMA Dose A · Biological: Measles and Rubella vaccine · Biological: Yellow Fever vaccine

  • Active comparator
    Infants_9M_Control A Group

    Infants, 9 months of age, will receive 2 doses of the MenACWY vaccine at Day 1 and Day 85 and 1 dose of the DTPa-HBV-IPV+Hib vaccine at Day 169. These infants will also receive an EPI vaccination with MR-VAC and YF vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.

    Biological: MenACWY · Combination Product: DTPa-HBV-IPV+Hib · Biological: Measles and Rubella vaccine · Biological: Yellow Fever vaccine

  • Experimental
    Infants_9M_Dose B Group

    Infants, 9 months of age, will receive 3 doses of the iNTS-GMMA Dose B (medium dose) vaccine at Day 1, Day 85 and Day 169. These infants will also receive an EPI vaccination withMR-VAC and YF vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.

    Biological: iNTS-GMMA Dose B · Biological: Measles and Rubella vaccine · Biological: Yellow Fever vaccine

  • Active comparator
    Infants_9M_Control B Group

    Infants, 9 months of age, will receive 2 doses of the MenACWY vaccine at Day 1 and Day 85 and 1 dose of the DTPa-HBV-IPV+Hib vaccine at Day 169. These infants will also receive an EPI vaccination with MR-VAC and YF vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.

    Biological: MenACWY · Combination Product: DTPa-HBV-IPV+Hib · Biological: Measles and Rubella vaccine · Biological: Yellow Fever vaccine

  • Experimental
    Infants_9M_Dose C Group

    Infants, 9 months of age, will receive 3 doses of the iNTS-GMMA Dose C (high dose) vaccine at Day 1, Day 85 and Day 169. These infants will also receive an EPI vaccination with MR-VAC and YF vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.

    Biological: iNTS-GMMA Dose C · Biological: Measles and Rubella vaccine · Biological: Yellow Fever vaccine

  • Active comparator
    Infants_9M_Control C Group

    Infants, 9 months of age, will receive 2 doses of the MenACWY vaccine at Day 1 and Day 85 and 1 dose of the DTPa-HBV-IPV+Hib vaccine at Day 169. These infants will also receive an EPI vaccination with MR-VAC and YF vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.

    Biological: MenACWY · Combination Product: DTPa-HBV-IPV+Hib · Biological: Measles and Rubella vaccine · Biological: Yellow Fever vaccine

  • Experimental
    Infants_6W_Dose A Group

    Infants, 6 weeks of age, will receive 3 doses of the iNTS-GMMA Dose A (low dose) vaccine at Day 1, Day 57 and at Day 232. These infants will also receive an EPI vaccination with MR-VAC and YF vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.

    Biological: iNTS-GMMA Dose A · Biological: Measles and Rubella vaccine · Biological: Yellow Fever vaccine

  • Active comparator
    Infants_6W_Control A Group

    Infants, 6 weeks of age, will receive 3 doses of the MenACWY vaccine at Day 1, Day 57 and at Day 232 To allow completion of the vaccination schedule, a fourth dose of the MenACWY vaccine is administered after the trial ends, as per the licensed indication and in private vaccination settings. These infants also will receive an EPI vaccination with MR-VAC and YF vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.

    Biological: MenACWY · Biological: Measles and Rubella vaccine · Biological: Yellow Fever vaccine

  • Experimental
    Infants_6W_Dose B Group

    Infants, 6 weeks of age, will receive 3 doses of the iNTS-GMMA Dose B (medium dose) vaccine at Day 1, Day 57 and at Day 232. These infants will also receive an EPI vaccination with MR-VAC and YF vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.

    Biological: iNTS-GMMA Dose B · Biological: Measles and Rubella vaccine · Biological: Yellow Fever vaccine

  • Active comparator
    Infants_6W_Control B Group

    Infants ,6 weeks of age, will receive 3 doses of the MenACWY vaccine at Day 1, Day 57 and at Day 232. To allow completion of the vaccination schedule, a fourth dose of the MenACWY vaccine is administered after the trial ends, as per the licensed indication and in private vaccination settings. These infants will also receive an EPI vaccination with MR-VAC and YF vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.

    Biological: MenACWY · Biological: Measles and Rubella vaccine · Biological: Yellow Fever vaccine

  • Experimental
    Infants_6W_Dose C Group

    Infants ,6 weeks of age, will receive 3 doses of the iNTS-GMMA Dose C (high dose) vaccine at Day 1, Day 57 and at Day 232. These infants will also receive an EPI vaccination with MR-VAC and YF vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.

    Biological: iNTS-GMMA Dose C · Biological: Measles and Rubella vaccine · Biological: Yellow Fever vaccine

  • Active comparator
    Infants_6W_Control C Group

    Infants ,6 weeks of age, will receive 3 doses of the MenACWY vaccine at Day 1, Day 57 and at Day 232. To allow completion of the vaccination schedule, a fourth dose of the MenACWY vaccine is administered after the trial ends, as per the licensed indication and in private vaccination settings. These infants will also receive an EPI vaccination with MR-VAC and YF vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.

    Biological: MenACWY · Biological: Measles and Rubella vaccine · Biological: Yellow Fever vaccine

Interventions

  • BiologicaliNTS-GMMA Dose C

    -2 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1 and Day 57 to adults and children in the Adults\_Dose C and Children\_Dose C groups; -3 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose C group, and at Day 1, Day 57 and at Day 232 to infants in the Infants\_6W\_Dose C group.

  • BiologicaliNTS-GMMA Dose B

    -2 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1 and Day 57 to children in the Children\_Dose B group; -3 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose B group, and at Day 1, Day 57 and Day at 232 to infants in the Infants\_6W\_Dose B group.

  • BiologicaliNTS-GMMA Dose A

    3 doses of iNTS-GMMA Dose A vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose A group, and at Day 1, Day 57 and Day at 232 to infants in the Infants\_6W\_Dose A group.

  • BiologicalMenACWY

    -1 dose of MenACWY vaccine administered intramuscularly at Day 1 to adults in the Adults\_Control group; -2 doses of MenACWY vaccine administered intramuscularly at Day 1 and Day 57 to children in the Children\_Control B and Children\_Control C groups, and at Day 1 and Day 85 to infants in the Infants\_9M\_Control A, Infants\_9M\_Control B and Infants\_9M\_Control C groups; -3 doses of MenACWY vaccine administered intramuscularly at Day 1, Day 57 and at Day 232 to infants in the Infants\_6W\_Control A, Infants\_6W\_Control B and Infants\_6W\_Control C groups. A 4th dose of MenACWY vaccine is administered after the trial ends, to infants in the aforementioned study groups, as per the licensed indication and in private vaccination settings.

    Also known as: Menveo

  • Combination productDTPa-HBV-IPV+Hib

    1 dose of DTPa-HBV-IPV+Hib vaccine administered intramuscularly at Day 169 to infants in the Infants\_9M\_Control A, Infants\_9M\_Control B and Infants\_9M\_Control C groups.

    Also known as: Infanrix hexa

  • DrugPlacebo

    1 dose of Placebo administered intramuscularly at Day 57 to adults in the Adults\_Control group.

  • BiologicalMeasles and Rubella vaccine

    Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants\_9M\_Dose A, Infants\_9M\_Control A, Infants\_9M\_Dose B, Infants\_9M\_Control B, Infants\_9M\_Dose C and Infants\_9M\_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants\_6W\_Dose A, Infants\_6W\_Control A, Infants\_6W\_Dose B, Infants\_6W\_Control B, Infants\_6W\_Dose C and Infants\_6W\_Control C groups.

    Also known as: MR-VAC

  • BiologicalYellow Fever vaccine

    Yellow Fever vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants\_9M\_Dose A, Infants\_9M\_Control A, Infants\_9M\_Dose B, Infants\_9M\_Control B, Infants\_9M\_Dose C and Infants\_9M\_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants\_6W\_Dose A, Infants\_6W\_Control A, Infants\_6W\_Dose B, Infants\_6W\_Control B, Infants\_6W\_Dose C and Infants\_6W\_Control C groups.

06

What researchers measure

Primary outcomes

  1. Number of adult participants 18-50 years of age with solicited administration site events

    The solicited administration site events are pain, redness and swelling.

    Time frame: During 7 days after the first study intervention administration occurring at Day 1

  2. Number of adult participants 18-50 years of age with solicited administration site events

    The solicited administration site events are pain, redness and swelling.

    Time frame: During 7 days after the second study intervention administration occurring at Day 57

  3. Number of adult participants 18-50 years of age with solicited systemic events

    The solicited systemic events are fever, headache, myalgia, arthralgia and fatigue. Fever is defined as axillary temperature higher than or equal to (\>=) 38.0 degrees Celsius (°C)/100.4 degrees Fahrenheit (°F).

    Time frame: During 7 days after the first study intervention administration occurring at Day 1

  4. Number of adult participants 18-50 years of age with solicited systemic events

    The solicited systemic events are fever, headache, myalgia, arthralgia and fatigue. Fever is defined as axillary temperature \>= 38.0 °C/100.4 degrees °F.

    Time frame: During 7 days after the second study intervention administration occurring at Day 57

  5. Number of adult participants 18-50 years of age with unsolicited adverse events (AEs)

    An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.

    Time frame: During 28 days after the first study intervention administration occurring at Day 1

  6. Number of adult participants 18-50 years of age with unsolicited adverse events (AEs)

    An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.

    Time frame: During 28 days after the second study intervention administration occurring at Day 57

  7. Number of adult participants 18-50 years of age with serious adverse events (SAEs)

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in abnormal pregnancy outcomes.

    Time frame: From first study intervention administration (Day 1) up to the end of study participation (Day 85)

  8. Number of adult participants 18-50 years of age with adverse events (AEs) leading to withdrawal from the study or discontinuation of study intervention

    An AE is any untoward medical occurrence (an unfavorable/unintended sign - including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention. The AE may or may not be considered related to the study intervention. Any AEs that lead to discontinuation of study intervention and/or the study are considered under this outcome measure.

    Time frame: From first study intervention administration (Day 1) up to the end of study participation (Day 85)

  9. Number of adult participants 18-50 years of age with deviations from reference ranges or baseline values for hematological, renal and hepatic panel test results

    Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

    Time frame: At Day 8 (7 days after the first study intervention administration)

  10. Number of adult participants 18-50 years of age with deviations from reference ranges or baseline values for hematological, renal and hepatic panel test results

    Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

    Time frame: At Day 64 (7 days after the second study intervention administration)

  11. Number of child participants 24-59 months of age with solicited administration site events

    The solicited administration site events are pain, redness and swelling.

    Time frame: During 7 days after the first study intervention administration occurring at Day 1

  12. Number of child participants 24-59 months of age with solicited administration site events

    The solicited administration site events are pain, redness and swelling.

    Time frame: During 7 days after the second study intervention administration occurring at Day 57

  13. Number of child participants 24-59 months of age with solicited systemic events

    The solicited systemic events are fever, irritability/fussiness, loss of appetite, drowsiness and vomiting. Fever is defined as axillary temperature \>= 38.0 °C/100.4 degrees °F.

    Time frame: During 7 days after the first study intervention administration occurring at Day 1

  14. Number of child participants 24-59 months of age with solicited systemic events

    The solicited systemic events are fever, irritability/fussiness, loss of appetite, drowsiness and vomiting. Fever is defined as axillary temperature \>= 38.0 °C/100.4 degrees °F.

    Time frame: During 7 days after the second study intervention administration occurring at Day 57

  15. Number of child participants 24-59 months of age with unsolicited AEs

    Time frame: During 28 days after the first study intervention administration occurring at Day 1

  16. Number of child participants 24-59 months of age with unsolicited AEs

    Time frame: During 28 days after the second study intervention administration occurring at Day 57

  17. Number of child participants 24-59 months of age with serious adverse events (SAEs)

    Time frame: From first study intervention administration (Day 1) up to the end of study participation (Day 85)

  18. Number of child participants 24-59 months of age with AEs leading to withdrawal from the study or discontinuation of study intervention

    Time frame: From first study intervention administration (Day 1) up to the end of study participation (Day 85)

  19. Number of child participants 24-59 months of age with deviations from reference ranges or baseline values for hematological, renal and hepatic panel test results

    Time frame: At Day 8 (7 days after the first study intervention administration)

  20. Number of child participants 24-59 months of age with deviations from reference ranges or baseline values for hematological, renal and hepatic panel test results

    Time frame: At Day 64 (7 days after the second study intervention administration)

  21. Number of infant participants 9 months of age with solicited administration site events

    The solicited administration site events are pain, redness and swelling.

    Time frame: During 7 days after the first study intervention administration occurring at Day 1

  22. Number of infant participants 9 months of age with solicited administration site events

    The solicited administration site events are pain, redness and swelling.

    Time frame: During 7 days after the second study intervention administration occurring at Day 85

  23. Number of infant participants 9 months of age with solicited administration site events

    The solicited administration site events are pain, redness and swelling.

    Time frame: During 7 days after the third study intervention administration occurring at Day 169

  24. Number of infant participants 9 months of age with solicited systemic events

    The solicited systemic events are fever, irritability/fussiness, loss of appetite, drowsiness, and vomiting. Fever is defined as axillary temperature \>= 38.0 °C/100.4 degrees °F.

    Time frame: During 7 days after the first study intervention administration occurring at Day 1

  25. Number of infant participants 9 months of age with solicited systemic events

    The solicited systemic events are fever, irritability/fussiness, loss of appetite, drowsiness, and vomiting. Fever is defined as axillary temperature \>= 38.0 °C/100.4 degrees °F.

    Time frame: During 7 days after the second study intervention administration occurring at Day 85

  26. Number of infant participants 9 months of age with solicited systemic events

    The solicited systemic events are fever, irritability/fussiness, loss of appetite, drowsiness, and vomiting. Fever is defined as axillary temperature \>= 38.0 °C/100.4 degrees °F.

    Time frame: During 7 days after the third study intervention administration occurring at Day 169

  27. Number of infant participants 9 months of age with unsolicited adverse events (AEs)

    Time frame: During 28 days after the first study intervention administration occurring at Day 1

  28. Number of infant participants 9 months of age with unsolicited adverse events (AEs)

    Time frame: During 28 days after the second study intervention administration occurring at Day 85

  29. Number of infant participants 9 months of age with unsolicited adverse events (AEs)

    Time frame: During 28 days after the third study intervention administration occurring at Day 169

  30. Number of infant participants 9 months of age with serious adverse events (SAEs)

    Time frame: From first study intervention administration (Day 1) up to the end of study participation (Day 337)

  31. Number of infant participants 9 months of age with adverse events (AEs) leading to withdrawal from the study or discontinuation of study intervention

    Time frame: From first study intervention administration (Day 1) up to the end of study participation (Day 337)

  32. Number of infant participants 9 months of age with deviations from reference range or baseline values for hematological, renal and hepatic panel test results

    Time frame: At Day 8 (7 days after the first study intervention administration)

  33. Number of infant participants 9 months of age with deviations from reference range or baseline values for hematological, renal and hepatic panel test results

    Time frame: At Day 92 (7 days after the second study intervention administration)

  34. Number of infant participants 9 months of age with deviations from reference range or baseline values for hematological, renal and hepatic panel test results

    Time frame: At Day 176 (7 days after the third study intervention administration)

  35. Number of infant participants 6 weeks of age with solicited administration site events

    The solicited administration site events are pain, redness and swelling.

    Time frame: During 7 days after the first study intervention administration occurring at Day 1

  36. Number of infant participants 6 weeks of age with solicited administration site events

    The solicited administration site events are pain, redness and swelling.

    Time frame: During 7 days after the second study intervention administration occurring at Day 57

  37. Number of infant participants 6 weeks of age with solicited systemic events

    The solicited systemic events are fever, irritability/fussiness, loss of appetite, drowsiness, and vomiting. Fever is defined as axillary temperature \>= 38.0 °C/100.4 degrees °F.

    Time frame: During 7 days after the first study intervention administration occurring at Day 1

  38. Number of infant participants 6 weeks of age with solicited systemic events

    The solicited systemic events are fever, irritability/fussiness, loss of appetite, drowsiness, and vomiting. Fever is defined as axillary temperature \>= 38.0 °C/100.4 degrees °F.

    Time frame: During 7 days after the second study intervention administration occurring at Day 57

  39. Number of infant participants 6 weeks of age with unsolicited adverse events (AEs)

    Time frame: During 28 days after the first study intervention administration occurring at Day 1

  40. Number of infant participants 6 weeks of age with unsolicited adverse events (AEs)

    Time frame: During 28 days after the second study intervention administration occurring at Day 57

  41. Number of infant participants 6 weeks of age with SAEs

    Time frame: From first study intervention administration (Day 1) up to 28 days after second study intervention (Day 85)

  42. Number of infant participants 6 weeks of age with adverse events (AEs) leading to MR-VAC administration withdrawal from the study or discontinuation of study intervention

    Time frame: From first study intervention administration (Day 1) up to 28 days after second study intervention (Day 85)

  43. Number of infant participants 6 weeks of age with deviations from reference ranges or baseline values for hematological, renal, and hepatic panel test results

    Time frame: At Day 8 (7 days after the first study intervention administration)

  44. Number of infant participants 6 weeks of age with deviations from reference ranges or baseline values for hematological, renal, and hepatic panel test results at Day 64

    Time frame: At Day 64 (7 days after the second study intervention administration)

Secondary outcomes

  1. Number of infant participants 6 weeks of age with solicited administration site events

    The solicited administration site events are pain, redness and swelling.

    Time frame: During 7 days after the third study intervention administration occurring at Day 232

  2. Number of infant participants 6 weeks of age with solicited systemic events

    The solicited systemic events are fever, irritability/fussiness, loss of appetite, drowsiness, and vomiting. Fever is defined as axillary temperature \>= 38.0 °C/100.4 degrees °F.

    Time frame: During 7 days after the third study intervention administration occurring at Day 232

  3. Number of infant participants 6 weeks of age with unsolicited AEs

    Time frame: During 28 days after the third study intervention administration occurring at Day 232

  4. Number of infant participants 6 weeks of age with SAEs

    Time frame: From 28 days after the second study intervention administration (Day 85) up to end of study participation (Day 400)

  5. Number of infant participants 6 weeks of age with adverse events (AEs) leading to withdrawal from the study or withholding further study intervention administration

    Time frame: From 28 days after the second study intervention administration (Day 85) up to end of study participation (Day 400)

  6. Number of infant participants 6 weeks of age with deviations from reference ranges or baseline values for hematological, renal, and hepatic panel test results

    Time frame: At Day 239 (7 days after the study intervention administration)

  7. Anti-invasive nontyphoidal Salmonella (iNTS) serotype specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) in adult participants 18-50 years of age

    Anti-S. Typhimurium OAg total IgG and anti-S. Enteritidis OAg total IgG GMCs are assessed.

    Time frame: At Days 1 and 57 (before each study intervention administration) and at Days 29 and 85 (28 days after each study intervention administration)

  8. Anti-invasive nontyphoidal Salmonella (iNTS) serotype specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) in child participants 24-59 months of age

    Anti-S. Typhimurium OAg total IgG and anti-S. Enteritidis OAg total IgG GMCs are assessed.

    Time frame: At Days 1 and 57 (before each study intervention administration) and at Days 29 and 85 (28 days after each study intervention administration)

  9. Anti-invasive nontyphoidal Salmonella (iNTS) serotype specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) in infant participants 9 months of age

    Anti-S. Typhimurium OAg total IgG and anti-S. Enteritidis OAg total IgG GMCs are assessed.

    Time frame: At Days 1, 85 and 169 (before each study intervention administration) and at Days 29, 113 and 197 (28 days after each study intervention administration)

  10. Anti-invasive nontyphoidal Salmonella (iNTS) serotype specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) in infant participants 6 weeks of age

    Anti-S. Typhimurium OAg total IgG and anti-S. Enteritidis OAg total IgG GMCs are assessed.

    Time frame: At Days 1, 57 and 232 (before each study intervention administration) at Days 29, 85 and 260 (28 days after each study intervention administration) and at Day 239 (7 days after the third study intervention administration)

  11. Number of adult participants 18-50 years of age achieving, for each antigen (Ag), at least a 2-fold and 4-fold rise in anti-invasive nontyphoidal Salmonella (iNTS) serotype specific immunoglobulin G (IgG) antibody concentration

    Anti-S. Typhimurium OAg total IgG and anti-S. Enteritidis OAg total IgG antibody concentrations are assessed.

    Time frame: At Days 29 and 85 (28 days after each study intervention administration) compared to Day 1 (baseline, prior to first study intervention administration)

  12. Number of child participants 24-59 months of age achieving, for each antigen (Ag), at least a 2-fold and 4-fold rise in anti-invasive nontyphoidal Salmonella (iNTS) serotype specific immunoglobulin G (IgG) antibody concentration

    Anti-S. Typhimurium OAg total IgG and anti-S. Enteritidis OAg total IgG antibody concentrations are assessed.

    Time frame: At Days 29 and 85 (28 days after each study intervention administration) compared to Day 1 (baseline, prior to first study intervention administration)

  13. Number of infant participants 9 months of age achieving, for each antigen (Ag), at least a 2-fold and 4-fold rise in anti-invasive nontyphoidal Salmonella (iNTS) serotype specific immunoglobulin G (IgG) antibody concentration

    Anti-S. Typhimurium OAg total IgG and anti-S. Enteritidis OAg total IgG antibody concentrations are assessed.

    Time frame: At Days 29, 113 and 197 (28 days after each study intervention administration) compared to Day 1 (baseline, prior to first study intervention administration)

  14. Number of infant participants 6 weeks of age achieving, for each antigen (Ag), at least a 2-fold and 4-fold rise in anti-invasive nontyphoidal Salmonella (iNTS) serotype specific immunoglobulin G (IgG) antibody concentration

    Anti-S. Typhimurium OAg total IgG and anti-S. Enteritidis OAg total IgG antibody concentrations are assessed.

    Time frame: At Days 29, 85 and 260 (28 days after each study intervention administration) and at Day 239 (7 days after the third study intervention administration) compared to Day 1 (baseline, prior to first study intervention administration)

07

Study locations

1 site
  • GSK Investigational Site
    Kumasi, Ghana
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About\_GSK\_Patient\_Level\_Data\_Sharing\_Final\_13July2023.pdf

Supporting information: Study protocol, Sap, Icf, Csr

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06213506
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 19, 2024
Start date
Jan 15, 2024
Primary completion
Aug 6, 2026
Completion
Aug 6, 2026
Last update
Sep 21, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Salmonella Infections

Other studies from this sponsor

GlaxoSmithKline

Start the discussion